Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 141 participants.
Also called NCT01089790
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 141 participants
- Sponsor
- Registry
-
NCT01089790
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT01089790. Non-randomized; triple masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2010-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
- Acronym
- REDWOOD403
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dutogliptin
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- Forest Laboratories
- Collaborator
- Phenomix
Record details
- Record id
cardio:ct-nct01089790- Content hash
2547b6aa174f3d479ed570e2271010cd79a53f69dc508506616999f9d98ecfad